1. Comparison of renal safety and efficacy of telbivudine, entecavir and tenofovir treatment in chronic hepatitis B patients: real world experience 
M.-C. Tsai, C.-H. Chen, P.-L. Tseng, C.-H. Hung, K.-W. Chiu, J.-H. Wang, S.-N. Lu, C.-M. Lee, K.-C. Chang, Y.-H. Yen, M.-T. Lin, Y.-P. Chou, T.-H. Hu 
Clinical Microbiology and Infection 
Volume 22, Issue 1, Pages 95.e1-95.e7 (January 2016)
DOI: /j.cmi
Copyright © 2015 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

2. Fig. 1
Comparison the estimated glomerular filtration rate (eGFR) between entecavir (ETV), telbivudine (LdT) or tenofovir (TDF) -naive chronic hepatitis B (CHB). (a) Overall; (b) in eGFR >90 mL/min/1.73 m2 (c) in chronic kidney disease stage II.
Clinical Microbiology and Infection  , 95.e1-95.e7DOI: ( /j.cmi )
Copyright © 2015 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

3. Fig. 2
Comparison the change of estimated glomerular filtration rate (eGFR) between entecavir (ETV), telbivudine (LdT), or tenofovir (TDF)-naive chronic hepatitis B (CHB) from baseline to last visit. (a) Overall, (b) in eGFR >90 mL/min/1.73 m2, (c) in chronic kidney disease stage II, (d) without chemotherapy.
Clinical Microbiology and Infection  , 95.e1-95.e7DOI: ( /j.cmi )
Copyright © 2015 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

4. Fig. 3
Comparison cumulative hepatocellular carcinoma (HCC) incidence in naive chronic hepatitis B (CHB). (a) Overall, (b) between entecavir, telbivudine, and entecavir, (c) between virological breakthrough and non-virological breakthrough, and (d) between cirrhosis and non-cirrhosis.
Clinical Microbiology and Infection  , 95.e1-95.e7DOI: ( /j.cmi )
Copyright © 2015 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions